Eric Tam

POSTER: CT-105: Insurance Status, Neurotoxicity, and Clinical Outcomes After CAR-T Therapy in a Highly Socially Vulnerable Cohort

Zara Orozco, Omer Ashruf, Choo Phei Wee, Eric Tam

us (code pays fourni par la source)

POSTER: CT-385: Higher Early-Posttransplant Tacrolimus Levels Are Associated With Inferior Survival Outcomes After Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Hien Lau, Golbarg Rahimi, Brandon Tang, Ellie Gibbs et autres

us (code pays fourni par la source)

CT-105: Insurance Status, Neurotoxicity, and Clinical Outcomes After CAR-T Therapy in a Highly Socially Vulnerable Cohort

Zara Orozco, Omer Ashruf, Choo Phei Wee, Eric Tam

us (code pays fourni par la source)

CT-385: Higher Early-Posttransplant Tacrolimus Levels Are Associated With Inferior Survival Outcomes After Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Hien Lau, Golbarg Rahimi, Brandon Tang, Ellie Gibbs et autres

us (code pays fourni par la source)

Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives

Tiffany Chen, Grace Kim, Yekta Rahimi, Monisha Kamdar et autres

m). This manuscript reviews the molecular rationale of menin inhibition for aberrant homeobox/myeloid ectopic insertion site 1 (HOX/MEIS1)-driven gene expression and leukemogenesis, clinical trial outcomes, and safety data for menin inhibitors, with a focus on recently FDA-approved revumenib and several other agents …

us (code pays fourni par la source)

Acute Myeloid Leukemia With a Non-Canonical FLT3 V491L Mutation: A Case Report With Ex Vivo FLT3 Inhibitors Sensitivity Testing

Mateusz Pospiech, Michelle P. Ngo, Misk Alrawashdeh, Usama Qamar et autres

Approximately 30% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) mutations, which are associated with poor overall survival. Although United States Food and Drug Administration (FDA)-approved FLT3 inhibitors are available, their efficacy against non-canonical FLT3 mutations remains …

us, pk (code pays fourni par la source)

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Andrew Jonas, Sangeetha Venugopal, George Yaghmour, Manu Raj Pandey et autres

Abstract Background: Outcomes for relapsed or refractory (R/R) acute myeloid leukemia (AML) remain poor despite advances in the treatment of AML. MEC, consisting of mitoxantrone, etoposide (ETOP), and cytarabine, is an established regimen for the treatment of R/R AML. Peposertib is a …

us (code pays fourni par la source)

Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia

Alina Amin Muhammad, Erum Mir Ghazi, Amir Ali, Eric Tam et autres

Tyrosine kinase inhibitors (TKIs) have changed the prognosis of Philadelphia-positive B-cell acute lymphoblastic leukemia (ALL); however, relapsed and refractory disease after multiple TKIs continues to be a clinical challenge. Brexucabtagene autoleucel (brexu-cel) is a novel FDA-approved therapy for relapsed and refractory ALL. …

pk, us (code pays fourni par la source)

Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus

Karam Ashouri, Eduardo Fernández, Anush Ginosyan, Carissa M. Feliciano et autres

us (code pays fourni par la source)

First Reported Evaluation of Outcomes and Safety of Using “Flipped” Conditioning Regimens of Fractionated Total Body Irradiation Followed By Fludarabine Vs Cyclophosphamide for Allogeneic-Hematopoietic Stem Cell Transplant at the University of Southern California

Vincent Louie Mendiola, Denaly Chen, Jack Rodman, Amir Ali et autres

Outcomes of Myelofibrosis Patients in the Era of Using JAK2 Inhibitor with Allogeneic-HSCT at the University of Southern California, a Retrospective Study

Vincent Louie Mendiola, Krithika Chennapan, Denaly Chen, Jack Rodman et autres

MPN-215 Outcomes of Myelofibrosis Patients Post Allogeneic-HSCT at the University of Southern California, a Retrospective Study

Vincent Louie Mendiola, Krithika Chennapan, Denaly Chen, Jack Rodman et autres

us (code pays fourni par la source)